THE PURPOSE OF THIS PROJECT IS TO DEVELOP AND CHARACTERIZE MONOCLONAL ANTIBODIES WHICH CAN BE USED IN THE FORM OF RADIONUCLIDE IMMUNOCONJUGATES FOR IN VIVO IMAGING OF B-CELL LYMPHOMAS.

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: N/A
Agency Tracking Number: 3088
Amount: $50,000.00
Phase: Phase I
Program: SBIR
Awards Year: 1985
Solicitation Year: N/A
Solicitation Topic Code: N/A
Solicitation Number: N/A
Small Business Information
Neorx Corpon
410 West Harrison, Seattle, WA, 98119
DUNS: N/A
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 ROBERT W. SCHROFF
 PRINCIPAL INVESTIGATOR
 (206) 281-7001
Business Contact
Phone: () -
Research Institution
N/A
Abstract
THE PURPOSE OF THIS PROJECT IS TO DEVELOP AND CHARACTERIZE MONOCLONAL ANTIBODIES WHICH CAN BE USED IN THE FORM OF RADIONUCLIDE IMMUNOCONJUGATES FOR IN VIVO IMAGING OF B-CELL LYMPHOMAS. NO MONOCLONAL ANTIBODIES SPECIFIC FOR HUMAN B-CELL LYMPHOMAS OR LEUKEMIAS CURRENTLY EXIST. SUCH IMMUNOCONJUGATES WOULD BE OF DIAGNOSTIC VALUE FOR NON-HODGKINS B-CELL LYMPHOMA, OF WHICH THERE ARE APPROXIMATELY 15,000 NEW CASES PER YEAR IN THE U.S., AND POTENTIALLY REPLACE THE CURRENT DIAGNOSTIC PROCEDURES OF CT SCANS, LIVER-SPLEEN SCANS AND LYMPHANGIOGRAMS. IN ADDITION, DATA FROM CLINICAL DIAGNOSTIC IMAGING TRIALS WOULD PROVIDE AN INFORMATION BASE TO ASSESS THE FEASIBILITY OF EMPLOYING THE SAME ANTIBODIES IN THE FORM OF DRUG, TOXIN, OR RADIONUCLIDE THERAPEUTIC IMMUNOCONJUGATES WITH THE POTENTIAL FOR TREATMENT OF AN ADDITIONAL 20,000 NEW B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS PER YEAR. THE PHASE I PROJECT WILL BE COMPRISED OF FOUR COMPONENTS: PRODUCTION OF THE ANTIBODIES, IN VITRO CHARACTERIZATION OF ANTIBODY SELECTIVITY PATTERNS, DELINEATION OF THE EXTENT TO WHICH VARIOUS TUMOR CELLS ARE CAPABLE OF BINDING THE ANTIBODIES, IN VIVO ANIMAL STUDIES OF TUMOR CELL LOCALIZATION AND BIODISTRIBUTION. THE LATTER PHASE WOULD EMPLOY NEORX'S PROPRIETARY TECHNOLOGY FOR THE CHEMICAL COUPLING TO ANTIBODIES OF TECHNETIUM-99M, THE MOST WIDELY EMPLOYED RADIOISOTOPE IN NUCLEAR MEDICINE.

* information listed above is at the time of submission.

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government